Synovial sarcomas usually metastasize after >5 years: a multicenter retrospective analysis with minimum follow-up of 10 years for survivors

Annals of Oncology

Volumn 22, Issue 2, 2011, Pages 458-467

  Krieg, A H ^a   Hefti, F ^a   Speth, B M ^a   Jundt, G ^a   Guillou, L ^b   Exner, U G ^c   von Hochstetter, A R ^d   Cserhati, M D ^e   Fuchs, B ^f   Mouhsine, E ^g   Kaelin, A ^h   Klenke, F M ^b   Siebenrock, K A ^b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c Orthopaedic Research Center   (Switzerland)

^d Institute of Pathology Enge   (Switzerland)

^e Orthopaedic Practice   (Switzerland)

^f BALGRIST UNIVERSITY HOSPITAL   (Switzerland)

^g LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^h GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Follow up study; Metastasis; Sarcoma; Sarcoma surgery; Soft tissue neoplasms; Synovial sarcoma

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; METASTASIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL TIME; SYNOVIAL SARCOMA; TUMOR VOLUME;

EID: 79251579648     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq394     Document Type: Article

References (37)

1. Weiss S, Goldblum J, Publishing M. Enzinger and Weiss's Soft Tissue Tumors. St Louis, MI: Mosby 2001.
2. Milchgrub S, Ghandur-Mnaymneh L, Dorfman HD, Albores-Saavedra J. Synovial sarcoma with extensive osteoid and bone formation. Am J Surg Pathol 1993; 17: 357-363.
3. Miettinen M, Virtanen I. Synovial sarcoma-a misnomer. Am J Pathol 1984; 117: 18-25.
4. Smith ME, Fisher C, Wilkinson LS, Edwards JC. Synovial sarcoma lack synovial differentiation. Histopathology 1995; 26: 279-281.
5. Haldar M, Hancock JD, Coffin CM et al. A conditional mouse model of synovial sarcoma: insights into a myogenic origin. Cancer Cell 2007; 11: 375-388.
6. Lewis JJ, Antonescu CR, Leung DH et al. Synovial sarcoma: a multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity. J Clin Oncol 2000; 18: 2087-2094.
7. Okcu MF, Munsell M, Treuner J et al. Synovial sarcoma of childhood and adolescence: a multicenter, multivariate analysis of outcome. J Clin Oncol 2003; 21: 1602-1611.
8. Fletcher CDM, Unni KK, Mertens F. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon, France: IARC Press 2002.
9. Ferrari A, Gronchi A, Casanova M et al. Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. Cancer 2004; 101: 627-634.
10. Ladanyi M, Antonescu CR, Leung DH et al. Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res 2002; 62: 135-140.
11. Guillou L, Benhattar J, Bonichon F et al. Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis. J Clin Oncol 2004; 22: 4040-4050.
12. Kawai A, Woodruff J, Healey JH et al. SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N Engl J Med 1998; 338: 153-160.
13. Nilsson G, Skytting B, Xie Y et al. The SYT-SSX1 variant of synovial sarcoma is associated with a high rate of tumor cell proliferation and poor clinical outcome. Cancer Res 1999; 59: 3180-3184.
14. Singer S, Baldini EH, Demetri GD et al. Synovial sarcoma: prognostic significance of tumor size, margin of resection, and mitotic activity for survival. J Clin Oncol 1996; 14: 1201-1208.
15. Pisters PW, O'Sullivan B, Maki RG. Evidence-based recommendations for local therapy for soft tissue sarcomas. J Clin Oncol 2007; 25: 1003-1008.
16. Sakabe T, Murata H, Konishi E et al. Evaluation of clinical outcomes and prognostic factors for synovial sarcoma arising from the extremities. Med Sci Monit 2008; 14: CR305-C310.
17. Goodlad JR, Fletcher CD, Smith MA. Surgical resection of primary soft-tissue sarcoma. Incidence of residual tumour in 95 patients needing re-excision after local resection. J Bone Joint Surg Br 1996; 78: 658-661.
18. Maduekwe UN, Hornicek FJ, Springfield DS et al. Role of sentinel lymph node biopsy in the staging of synovial, epithelioid, and clear cell sarcomas. Ann Surg Oncol 2009; 16: 1356-1363.
19. Coindre JM. Histologic grading of adult soft tissue sarcomas. Verh Dtsch Ges Pathol 1998; 82: 59-63.
20. Coindre JM, Terrier P, Guillou L et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer 2001; 91: 1914-1926.
21. Guillou L, Coindre JM, Bonichon F et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol 1997; 15: 350-362.
22. Guillou L, Coindre J, Gallagher G et al. Detection of the synovial sarcoma translocation t(X;18) (SYT;SSX) in paraffin-embedded tissues using reverse transcriptase-polymerase chain reaction: a reliable and powerful diagnostic tool for pathologists. A molecular analysis of 221 mesenchymal tumors fixed in different fixatives. Hum Pathol 2001; 32: 105-112.
23. Kaplan EL, Meier P. Nonparametric estimations for incomplete Observations. J Am Stat Assoc 1958; 53: 457-481.
24. Peto R, Pike MC, Armitage P et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer 1977; 35: 1-39.
25. Brodsky JT, Burt ME, Hajdu SI et al. Tendosynovial sarcoma. Clinicopathologic features, treatment, and prognosis. Cancer 1992; 70: 484-489.
26. Oda Y, Hashimoto H, Tsuneyoshi M, Takeshita S. Survival in synovial sarcoma. A multivariate study of prognostic factors with special emphasis on the comparison between early death and long-term survival. Am J Surg Pathol 1993; 17: 35-44.
27. Okcu MF, Despa S, Choroszy M et al. Synovial sarcoma in children and adolescents: thirty three years of experience with multimodal therapy. Med Pediatr Oncol 2001; 37: 90-96.
28. Ladenstein R, Treuner J, Koscielniak E et al. Synovial sarcoma of childhood and adolescence. Report of the German CWS-81 study. Cancer 1993; 71: 3647-3655.
29. Takenaka S, Ueda T, Naka N et al. Prognostic implication of SYT-SSX fusion type in synovial sarcoma: a multi-institutional retrospective analysis in Japan. Oncol Rep 2008; 19: 467-476.
30. Spillane AJ, A'Hern R, Judson IR et al. Synovial sarcoma: a clinicopathologic, staging, and prognostic assessment. J Clin Oncol 2000; 18: 3794-3803.
31. Trassard M, Le Doussal V, Hacene K et al. Prognostic factors in localized primary synovial sarcoma: a multicenter study of 128 adult patients. J Clin Oncol 2001; 19: 525-534.
32. Cadman NL, Soule EH, Kelly PJ. Synovial sarcoma; an analysis of 34 tumors. Cancer 1965; 18: 613-627.
33. Wright PH, Sim FH, Soule EH, Taylor WF. Synovial sarcoma. J Bone Joint Surg Am 1982; 64: 112-122.
34. Mullen JR, Zagars GK. Synovial sarcoma outcome following conservation surgery and radiotherapy. Radiother Oncol 1994; 33: 23-30.
35. Bergh P, Meis-Kindblom JM, Gherlinzoni F et al. Synovial sarcoma: identification of low and high risk groups. Cancer 1999; 85: 2596-2607.
36. Oda Y, Hashimoto H, Takeshita S, Tsuneyoshi M. The prognostic value of immunohistochemical staining for proliferating cell nuclear antigen in synovial sarcoma. Cancer 1993; 72: 478-485.
37. ten Heuvel SE, Hoekstra HJ, Bastiaannet E, Suurmeijer AJ. The classic prognostic factors tumor stage, tumor size, and tumor grade are the strongest predictors of outcome in synovial sarcoma: no role for SSX fusion type or ezrin expression. Appl Immunohistochem Mol Morphol 2009; 17: 189-195.